Core Viewpoint - The article discusses the 12 most profitable blue-chip stocks to invest in currently, emphasizing the importance of diversification and identifying opportunities amidst market volatility [1][2][3]. Market Trends and Investment Strategy - Stephen Parker from JPMorgan Private Bank highlights that geopolitical events, such as the Iran war, can cause short-term market disruptions, particularly in energy markets, but typically do not have long-lasting effects [1][2]. - He advises clients to maintain a diversified and disciplined investment approach, seek opportunities during volatility, and start building a shopping list for potential investments [2][3]. Stock Selection Methodology - The selection of the 12 blue-chip stocks was based on stock screeners and holdings of blue-chip ETFs, focusing on those with the highest trailing twelve months (TTM) net income and net income margins [5]. - The list prioritizes stocks with the highest number of hedge fund holders as of Q3 2025, utilizing data from Insider Monkey's database [5][6]. Company Highlights - **AstraZeneca PLC (NASDAQ:AZN)**: - Price target raised to 16,000 GBp from 15,500 GBp by Guggenheim, maintaining a Buy rating after positive fiscal 2025 results [8]. - The FDA has accepted a supplemental Biologics License Application for Enhertu, with a Priority Review status for treating HER2-positive breast cancer [9][10]. - AstraZeneca focuses on developing and commercializing prescription medicines, including novel immuno-oncology treatments [11]. - **Johnson & Johnson (NYSE:JNJ)**: - Citi increased the price target to $274 from $250 while maintaining a Buy rating, citing healthy sector fundamentals despite recent volatility [12]. - The company submitted a Type II variation application to the EMA for TECVAYLI® to treat relapsed/refractory multiple myeloma [13][14]. - Johnson & Johnson operates in healthcare, with segments in Innovative Medicine and MedTech, covering various therapeutic areas and medical devices [15].

Core Viewpoint - The Court has granted preliminary approval for a $65 million settlement in an antitrust class action against Actelion Pharmaceuticals, now part of Johnson & Johnson, for allegedly preventing generic drug manufacturers from developing a cheaper version of its drug Tracleer [1] Group 1: Lawsuit Details - The lawsuit was initiated by the Government Employees Health Association (GEHA), which claimed that Actelion obstructed generic manufacturers from obtaining necessary samples of Tracleer, thereby hindering the market entry of generic alternatives [2] - GEHA alleged that Actelion not only refused to sell samples but also contractually prevented competitors from acquiring samples from pharmacies, effectively blocking all avenues for generic manufacturers [2] - The alleged actions resulted in no generic product being available for nearly four years after the Tracleer patent expired, leading to over $100 million in overpayments by GEHA and other Third-Party Payors for the drug [2] Group 2: Settlement and Impact - The settlement amount of $65 million represents nearly 50% of the conservative single damages estimate, providing significant relief to the class of entities that purchased Tracleer [3] - If finalized, the settlement will resolve over seven years of litigation and deliver compensation to those affected by the alleged antitrust practices [3] Group 3: Drug Information - Tracleer, the brand name for bosentan, is used to treat pulmonary artery hypertension (PAH), a chronic and potentially fatal condition affecting 10,000 to 20,000 people in the U.S., primarily women [4] - At the time of the alleged antitrust scheme, Actelion charged $75,000 per patient annually for Tracleer [4] Group 4: Legal Proceedings - The lawsuit was originally filed in 2018 but was dismissed in 2019 due to statute of limitations issues; however, the Fourth Circuit revived the case in 2021, allowing it to proceed [5] - The district court granted class certification for GEHA in September 2024, denying Actelion's motion for summary judgment, which set the stage for the trial [5]

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate- risk non-muscle-invasive bladder cancer Accessibility Statement Skip Navigation- Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer- Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profileRARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & ...

The European Commission delivered notable regulatory decisions this week - expanding the indication for Johnson & Johnson's prostate cancer therapy, approving a new dosing regimen for Protalix BioTherapeutics' enzyme replacement therapy Elfabrio, and granting a second indication to Incyte's immuno-oncology drug Zynyz.Johnson & Johnson (JNJ)On March 9, 2026, the European Commission approved Johnson & Johnson's AKEEGA with prednisone or prednisolone in combination with androgen deprivation therapy (ADT) for ...

Core Viewpoint - The article emphasizes the importance of investing in "Dividend Kings," which are companies that have consistently raised their dividends for over 50 years, especially in the current volatile market environment characterized by geopolitical tensions and economic uncertainty [1]. Group 1: Market Conditions - The stock market is facing potential challenges as extreme valuations, geopolitical tensions, and skepticism around AI investments converge, with the Warren Buffett indicator reaching approximately 220%, indicating a detachment from economic fundamentals [1]. - The ongoing U.S.-Iran conflict is contributing to rising oil prices, which may lead to supply shocks and inflation, complicating the economic landscape [1]. - Recent actions by BlackRock and Morgan Stanley to limit withdrawals from private credit funds signal increasing caution in the financial markets [1]. Group 2: Dividend Kings Overview - Dividend Kings are defined as companies that have raised their dividends for at least 50 years, making them attractive for passive-income investors seeking reliable income streams [1]. - The article highlights five specific Dividend Kings that are considered safe investments for the current market conditions, all rated as "Buy" by top Wall Street firms [1]. Group 3: Featured Dividend Kings - **Coca-Cola (KO)**: Offers a 2.65% dividend, with organic revenue growth of 5% in 2025 and projected growth of 4% to 5% in 2026. Analysts expect adjusted EPS growth of 7% to 8% [1]. - **Procter & Gamble (PG)**: Pays a 2.69% dividend and has raised dividends for 70 consecutive years. The company operates in various consumer goods segments and is known for its recession-resistant cash flows [2]. - **Johnson & Johnson (JNJ)**: A diversified healthcare company with a 2.12% dividend, trading at 14.5 times forward earnings. It has a strong reputation for stable cash flows and a diverse product portfolio [2]. - **S&P Global (SPGI)**: Provides essential market intelligence and pays a 0.88% dividend. The company operates across five business segments, including credit ratings and market analytics [2]. - **Lowe's Companies (LOW)**: A home improvement retailer with a 1.89% dividend, known for its strong market position and steady cash flow generation [2].

医药行业|行业研究报告 证券研究报告 2026/03 小核酸行业系列报告（一）：小核酸成药之路 —— Listening to the Sound of Silence: The Road to RNA Therapeutics 戎晓婕 S1190525070001 证券分析师： 分析师登记编号： 周豫 S1190523060002 证券分析师： 分析师登记编号： 核心观点 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 ◼ 小核酸药物通过RNA层面调控打开传统药物难以触达的靶点空间，已完成从技术验证到商业兑现的 跨越。2025年主要ASO、siRNA上市药物销售额分别约31亿美元、42亿美元。 ◼ 机制差异塑造了两条发展路径。ASO为单链结构，可通过鞘内给药/Gymnosis机制实现裸ASO进入目 标组织细胞，率先突破CNS、肌肉等领域，疗效提升依赖于化学修饰对分子稳定性与亲和力的优化； siRNA为双链形式，结构相对稳定但分子量较大且带强负电荷，需要依托载体实现有效递送；RISC 介导的催化切割赋予更强沉默效率，GalNAc技术成熟后，siRNA在肝靶向实现弯道超越。 ◼ 化学修饰历经四代迭代， ...

药渡每周渡选 26年3月2日-3月8日 药渡团队 药渡经纬信息科技（北京）有限公司 https://data.pharmacodia.com/ 目录 全 球生 物 医药 行业 动 态 全 球生 物 医药 行业 重大事件 全 球创 新 药 重 要 临 床 进 展/ 结果 全 球 创 新 药重要 投融资与交易 事 件 全球 医药 监 管动 态 （批 准上市 / I N D / 特 殊 审 评 ） 01全球生物医药行业动态 资本市场方面：产业合作与融资并购密集落地：德琪医药将 CD3/CD19 双抗全球权益授权优时比，最高获 11.8 亿美元；中国生 物制药与赛诺菲就罗伐昔替尼达成独家授权，最高可获 15.3 亿美元；齐鲁制药与爱科百发达成多动症新药合作，后者最高获 4.7 亿元里程碑付款。Candid 通过合并上市完成 5.05 亿美元融资，五和博澳递交港交所招股书拟上市。质肽生物、新码生物分别完 成超 5 亿、6.29 亿人民币融资，莱芒生物、易慕峰各获近 2 亿融资，深度智耀三月累计融资 1.5 亿美元，多家生物企业完成不同 轮次融资，黑石 4 亿美元押注梯瓦制药单抗研发。 临床进展方面：代谢、肿瘤、免疫等领 ...

Johnson & Johnson will expand its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of TECNIS Odyssey IOL in India.The new full visual range IOL offers high-quality and continuous vision with unmatched range. This will allow patients to see clearly across all ranges minimizing their need for glasses.Built on the industry-leading TECNIS platform, combining advanced optics and proprietary materials, TECNIS Odyssey IOL offers consistently clear, high-contrast vision, said the com ...

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in cataract surgery. The company identified Tecnis PureSee as ...

For Immediate ReleasesChicago, IL – March 12, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include  JPMorgan Chase & Co. (JPM) , Johnson & Johnson (JNJ) , Applied Materials, Inc. (AMAT) and Value Line, Inc. (VALU) .Here are highlights from Thursday’s Analyst Blog:Top Research Reports for JPMorgan, Johnson & Johnson and ...